Back to News
Market Impact: 0.22
IDEXX Stock Gains Following the Acquisition of CoVet
Source: zacks.com
M&A & RestructuringArtificial IntelligenceTechnology & InnovationHealthcare & Biotech
IDEXX Laboratories shares rose 0.6% after the company acquired CoVet, an AI-native software provider. The acquisition expands IDEXX's capabilities in veterinary workflows, diagnostics and practice-performance tools, supporting its technology offering in the veterinary market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
IDXX0.58
More News
- Ryanair CEO warns fares could rise by up to 20% in 2027 as fuel bill jumps by $2.2 billion
- The AI trade has broken down. How we got here and what investors should expect next
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- NUBURU Completes Tekne Acquisition, Adding a $93 Million Defense & Dual-Use Program Portfolio and Advancing Expansion Across NATO and Allied Markets
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Aehr Test Systems earnings on deck amid AI chip boom